Concurrent radiochemotherapy in advanced hypopharyngeal cancer

被引:12
|
作者
Krstevska, Valentina [1 ]
Stojkovski, Igor [1 ]
Lukarski, Dusko [2 ]
机构
[1] Univ Clin Radiotherapy & Oncol, Dept Head & Neck Canc, Skopje, North Macedonia
[2] Univ Clin Radiotherapy & Oncol, Dept Radiat Phys, Skopje, North Macedonia
关键词
SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; ONCOLOGY GROUP RTOG; RADIATION-THERAPY; NECK-CANCER; ADVANCED LARYNGEAL; RANDOMIZED-TRIAL; ACCELERATED RADIOTHERAPY; EUROPEAN-ORGANIZATION; ORGAN PRESERVATION;
D O I
10.1186/1748-717X-5-39
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Concurrent platinum-based radiochemotherapy has been recommended as a standard of care in patients with locally advanced squamous cell head and neck carcinomas. Unfortunately, there is a lack of level one evidence on best treatment approach for advanced hypopharyngeal cancer. This report aims to summarize the results of our study on concurrent radiochemotherapy in patients with advanced hypopharyngeal cancer. Methods: A retrospective analysis of 41 patients with stage III-IV hypopharyngeal cancer was performed. All patients were treated with three dimensional conformal radiotherapy and received 70 Gy in 35 fractions (2 Gy per fraction, 5 fractions per week). In dependence of the period when radiotherapy was realized, two different treatment techniques were used. Concurrent chemotherapy consisted of cisplatin 30 mg/m(2) given on a weekly basis. Results: The median age was 52 years (range 29-70). Stage IV disease was recognized in 73.2% of the patients. Complete response rates at the primary site and at the metastatic neck lymph nodes were 68.3% and 36.6%, respectively. A complete composite response was present in 27 patients (65.9%). Median follow-up was 13 months (range 7-36). Distant metastases as initial failure occurred in 7 patients (46.7%). The 2-year local relapse-free survival and regional relapse-free survival rates were 55.2% and 75.8%, respectively. The 2-year locoregional relapse-free survival rate was 51.3%. The 2-year disease-free survival and overall survival rates were 29.3% and 32.8%, respectively. Confluent mucositis was developed in 46.3% of patients. Leucopenia grade 1 was the most frequent hematological toxicity. The median weight loss at the end of treatment was 12% (range 5-21). The worst grade of late toxicity was most commonly pronounced in the skin and in the subcutaneous tissue. Conclusions: Based on unsatisfactory results in our study we suggest that the use of sequential radiochemotherapy or chemotherapy given concomitantly with altered fractionation radiotherapy with the implementation of intensity-modulated radiotherapy as radiotherapy technique could represent treatment approaches able to improve outcome in patients with advanced hypopharyngeal cancer.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Neoadjuvant radiochemotherapy for locally advanced gastric cancer
    Anghel, R.
    Minea, L.
    Oprea, L.
    Georgescu, V
    Primejdie, V
    Popescu, I
    ANNALS OF ONCOLOGY, 2007, 18 : VII53 - VII53
  • [42] Results of radiotherarpy in locally advanced hypopharyngeal cancer
    Yoon, M. S.
    Chung, W-K.
    Sung, J. A.
    Nam, T. K.
    Nah, B. S.
    Lim, S-C.
    Cho, J-S.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S351 - S351
  • [43] Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
    Dellas, Kathrin
    Hoehler, Thomas
    Reese, Thomas
    Wuerschmidt, Florian
    Engel, Erik
    Roedel, Claus
    Wagner, Wolfgang
    Richter, Michael
    Arnold, Dirk
    Dunst, Juergen
    RADIATION ONCOLOGY, 2013, 8
  • [44] Adjuvant radiochemotherapy in locally advanced gastric cancer
    Martin Sanchez, Mercedes
    Perez Escutia, Maria Angeles
    Lora Pablos, David
    Guardado Gonzales, Sandra
    Cabezas Mendoza, Ana Maria
    Campos Bonel, Arantxa
    Perez Montero, Hector
    D'Ambrosi, Rafael
    Perez-Regadera Gomez, Jose Fermin
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (12) : 1005 - 1013
  • [45] Simultaneous radiochemotherapy & brachytherapy for advanced cervical cancer
    Rovirosa, A
    Fernández, J
    Almendral, P
    Jorcano, S
    Mellado, B
    Lejarcegui, J
    Pahisa, J
    Torné, A
    Molina, R
    Biete, A
    RADIOTHERAPY AND ONCOLOGY, 2005, 75 : S48 - S48
  • [46] Triapine Radiochemotherapy in Advanced Stage Cervical Cancer
    Kunos, Charles A.
    Ivy, S. Percy
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [47] Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer
    Eich, Hans Theodor
    Stepien, Anna
    Zimmermann, Christian
    Hellmich, Martin
    Metzger, Ralf
    Hoelscher, Arnulf
    Mueller, Rolf-Peter
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (04) : 225 - 230
  • [48] Advanced hypopharyngeal cancer with amyotrophic lateral sclerosis
    Kogashiwa, Yasunao
    Oishi, Naoki
    Yamauchi, Kohichi
    Kohno, Naoyuki
    AURIS NASUS LARYNX, 2011, 38 (06) : 750 - 752
  • [49] ADVANCED HYPOPHARYNGEAL CANCER - ADEQUACY OF RESECTION AND RECONSTRUCTION
    BLACK, RJ
    MEDICAL AND PEDIATRIC ONCOLOGY, 1985, 13 (03): : 149 - 149
  • [50] Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
    Buntzel, J
    Kuttner, K
    Frohlich, D
    Glatzel, M
    ANNALS OF ONCOLOGY, 1998, 9 (05) : 505 - 509